The interplay between thyroid and liver: implications for clinical practice.
Piantanida E, Ippolito S, Gallo D, Masiello E, Premoli P, Cusini C, Rosetti S, Sabatino J, Segato S, Trimarchi F, Bartalena L, Tanda ML.
J Endocrinol Invest. 2020 Jul;43(7):885-899. doi: 10.1007/s40618-020-01208-6. Epub 2020 Mar 12.
Severe myopathy in patients with thyrotoxicosis.
Hashizume K.
Intern Med. 2000 Jun;39(6):442-3. doi: 10.2169/internalmedicine.39.442.
Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study.
Groeneweg S, van Geest FS, Abacı A, Alcantud A, Ambegaonkar GP, Armour CM, Bakhtiani P, Barca D, Bertini ES, van Beynum IM, Brunetti-Pierri N, Bugiani M, Cappa M, Cappuccio G, Castellotti B, Castiglioni C, Chatterjee K, de Coo IFM, Coutant R, Craiu D, Crock P, DeGoede C, Demir K, Dica A, Dimitri P, Dolcetta-Capuzzo A, Dremmen MHG, Dubey R, Enderli A, Fairchild J, Gallichan J, George B, Gevers EF, Hackenberg A, Halász Z, Heinrich B, Huynh T, Kłosowska A, van der Knaap MS, van der Knoop MM, Konrad D, Koolen DA, Krude H, Lawson-Yuen A, Lebl J, Linder-Lucht M, Lorea CF, Lourenço CM, Lunsing RJ, Lyons G, Malikova J, Mancilla EE, McGowan A, Mericq V, Lora FM, Moran C, Müller KE, Oliver-Petit I, Paone L, Paul PG, Polak M, Porta F, Poswar FO, Reinauer C, Rozenkova K, Menevse TS, Simm P, Simon A, Singh Y, Spada M, van der Spek J, Stals MAM, Stoupa A, Subramanian GM, Tonduti D, Turan S, den Uil CA, Vanderniet J, van der Walt A, Wémeau JL, Wierzba J, de Wit MY, Wolf NI, Wurm M, Zibordi F, Zung A, Zwaveling-Soonawala N, Visser WE.
Lancet Diabetes Endocrinol. 2020 Jul;8(7):594-605. doi: 10.1016/S2213-8587(20)30153-4.
Endocrine myopathies.
Ruff RL, Weissmann J.
Neurol Clin. 1988 Aug;6(3):575-92.
3,3',5-Triiodothyroacetic Acid Transporters.
Chen Z, Yildiz S, Markova B, de Rooij LJ, Leeuwenburgh S, Hamers T, Peeters RP, Heuer H, Meima ME, Visser WE.
Thyroid. 2024 Aug;34(8):1027-1037. doi: 10.1089/thy.2023.0467. Epub 2024 Jul 3.
Thyrotoxic myopathy: research status, diagnosis, and treatment.
Cui H, Zhang X.
Endokrynol Pol. 2022;73(1):157-162. doi: 10.5603/EP.a2022.0004. Epub 2022 Feb 4.
Thyrotoxic muscle disease.
Ramsay I.
Postgrad Med J. 1968 May;44(511):385-97. doi: 10.1136/pgmj.44.511.385.
Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease.
Setoyama D, Lee HY, Moon JS, Tian J, Kang YE, Lee JH, Shong M, Kang D, Yi HS.
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):355-367. doi: 10.1002/jcsm.12889. Epub 2021 Dec 30.
Tyreotoksisk periodisk paralyse.
Ho APT, Tjønnfjord EB, Moe RB.
Tidsskr Nor Laegeforen. 2024 Apr 30;144(9). doi: 10.4045/tidsskr.23.0736. Print 2024 Aug 20.
Thyrotoxic Channelopathies.
Singhai P, Krishnan S, Patil VU.
J Assoc Physicians India. 2017 Nov;65(11):98-99.
